Ranked by how under-served they are by other creators right now. Zora · 2026-06-10
Just dropped. 25 million cannabis users across Europe + the agency flagging a decade-long potency surge as a public-health concern.
Why it's good for you: US-focused creators almost never cover EU drug-policy data. Lots of receipts, regulatory tension you can argue both sides of, fresh angle for your audience.
Illinois just went to 60g (was 30g). Vermont raised the threshold to 2oz. Massachusetts went 1oz → 2oz too. All this year.
Why it's good: super concrete, easy to visualize, and quietly normalizing. Very under-talked-about for how big a shift it actually is.
First plant-touching US company to list on a major American exchange. Ticker TRLV. This is the result of acting AG Todd Blanche's April rescheduling of state-licensed medical cannabis to Schedule III.
Why it's good: mainstream is covering the listing itself, but the chain that got us here (Schedule III, regulatory positioning, what this signals for the rest of the industry) is way under-explored. Plenty of angle.
Source for daily monitoring: marijuanamoment.net has a daily cannabis newsletter that's a goldmine.
Want me to pull more detail on any of those, or search for something else? Just text back.
— Z